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Osteoarthritis is the most common musculoskeletal disease and the leading cause of disability 
globally. Here, we perform the largest genome-wide association study for osteoarthritis to date 
(77,052 cases and 378,169 controls), analysing 4 phenotypes: knee osteoarthritis, hip 
osteoarthritis, knee and/or hip osteoarthritis, and any osteoarthritis. We discover 64 signals, 52 of 
them novel, more than doubling the number of established disease loci. Six signals fine map to a 
single variant. We identify putative effector genes by integrating eQTL colocalization, fine-
mapping, human rare disease, animal model, and osteoarthritis tissue expression data. We find 
enrichment for genes underlying monogenic forms of bone development diseases, and for the 
collagen formation and extracellular matrix organisation biological pathways. Ten of the likely 
effector genes, including TGFB1, FGF18, CTSK and IL11 have therapeutics approved or in clinical 
trials, with mechanisms of action supportive of evaluation for efficacy in osteoarthritis. 
 
 
Osteoarthritis affects 40% of individuals over the age of 701, is a major cause of pain, comorbidity 
and mortality2. Ten million people in the UK alone suffer from osteoarthritis, with a total indirect 
cost to the economy of £14.8 billion per annum2. Disease management targets the main symptom 
(pain) and culminates in joint replacement surgery (1.76 million per year in the EU) with variable 
outcomes3. There is a clear and urgent need to translate genomic evidence into druggable 
mechanisms of disease aetiology and progression, to support the development of disease-modifying 
therapies for osteoarthritis. 
 
Here, we leverage the UK Biobank and arcOGEN resources to perform the largest genome-wide 
meta-analysis for osteoarthritis to date across ~17.5 million single nucleotide variants in up to 
455,221 individuals (Supplementary Figure 1). We identify 65 genome-wide significant variants at 64 
loci (P≤3x10-8; Online Methods, Supplementary Table 1), 52 of which are novel, thus increasing the 
number of established loci from 344 to 86: 24 novel signals for osteoarthritis at any site (77,052 
cases), 15 for hip osteoarthritis (15,704 cases), 7 for knee osteoarthritis (24,955 cases), and 6 for 
osteoarthritis of the hip and/or knee (39,427 cases) (Table 1; Supplementary Table 2; Supplementary 
Figures 2-6). We find that 25 of 34 previously-reported loci show association (P<0.05) with at least 
one of the four osteoarthritis traits we evaluate (Supplementary Table 3).  
 
To identify putative effector genes at the 64 genome-wide significant regions, we integrated results 
from several strands of investigation, including transcriptomic/proteomic characterisation of primary 
tissue from osteoarthritis patients undergoing joint replacement surgery, coupled with statistical 
fine-mapping, annotation of predicted consequences of variants in the credible sets, eQTL 
colocalization, and relevant rare human disease and animal model evidence (Online Methods; 
Supplementary Table 4 and 5). We observe evidence of colocalization in at least one tissue for 49 
out of the 64 loci, 44 of which are at newly-associated osteoarthritis signals (Supplementary Table 
6). Using MetaXcan, we identify 11 genes with additional evidence of colocalization at loci not 
reaching genome-wide significance in SNV analyses (Supplementary Figure 7; Supplementary Tables 
7-8). 
 
Pathway analyses (Online Methods, Supplementary Note) identify 64 biological processes associated 
with osteoarthritis, of which 46 are bone-, cartilage- and chondrocyte- morphology related 
(Supplementary Table 9). The collagen formation and extracellular matrix organisation biological 
pathways are consistently identified by different pathway analysis methods. Genome-wide linkage 
disequilibrium (LD) score regression analysis5,6 unveils significant correlation between osteoarthritis 
and traits within the obesity, cognition, smoking, bone mineral density and reproductive trait 
categories (Figure 1; Supplementary Table 10 and 11). Mendelian randomization analyses (Online 
Methods) support a role for higher body mass index (BMI) and adiposity in osteoarthritis risk, and 
identify a potential protective effect of LDL cholesterol, and of higher level of education against 
osteoarthritis (Supplementary Tables 12-14, Supplementary Note). Two of the BMI loci (SLC39A8 and 
FTO) show genome-wide significant associations with osteoarthritis, with SLC39A8 showing much 
larger effects on osteoarthritis than expected given the BMI-raising effects (Supplementary Figure 8). 
Apparent causal associations of knee pain with osteoarthritis (Supplementary Table 12 and 15) are 
potentially attributable to reverse causality (Supplementary Note). We estimate the proportion of 
the total narrow sense heritability explained by osteoarthritis loci to be 14.7 % for knee 
osteoarthritis, 51.9 % for hip osteoarthritis, 24.2% for osteoarthritis of the hip and/or knee, and 
22.5% of osteoarthritis at any site (Supplementary Table 16). We do not find evidence for a role of 
low-frequency or rare variation of large effect in osteoarthritis susceptibility, and have limited power 
to detect smaller effects at lower-frequency variants (Figure 2). In the future, meta-analyses of 
osteoarthritis studies in global populations will help further deconvolute the genetic underpinning of 
this disabling disease. 
 
We used a combination of conditional analyses7 followed by asymptotic Bayes’ factor fine-mapping8 
(Online Methods) of conditionally distinct association signals to identify causal variants. In six of the 
novel loci, a single variant could be postulated as causal with more than 95% posterior probability: 
missense variants in SLC39A8, IL11 and ANAPC4 (rs13107325, rs4252548 and rs34811474, 
respectively), rs75621460 near TGFB1, rs547116051 near MAPT and rs528981060 near SCUBE1 
(Supplementary Table 17, Supplementary Note).  
 
We observe strong enrichment for genes known to cause monogenic bone development diseases 
and forms of early-onset osteoarthritis, in the vicinity of osteoarthritis signals (odds ratio [OR] 8.87, 
P=1.8x10-4, and OR 8.83, P=8x10-3, respectively) (Supplementary Table 18 and 19). This finding 
highlights bone development as an important physiological process in osteoarthritis aetiology. 
Several genes identified as likely causal in our study are also linked to osteoarthritis aetiology in 
animal models. In eight out of the ten cases where we can unequivocally define directionality of 
association, we observe concordance between our results and those from animal models (i.e. that 
reduced expression or loss-of-function mutations increase osteoarthritis risk both in humans and in 
animal models) (Supplementary Table 20). Some of these genes code for structural bone/cartilage 
proteins (COL11A1, COL11A2) or play a critical role in bone/cartilage development (FGFR3, GDF5). 
These consistent observations in human and animal models provide compelling evidence for a causal 
role of these genes in osteoarthritis and point to an agonist strategy as the desired mechanism of 
action for new osteoarthritis drugs targeting these eight genes.  
 
Ten genes have a therapeutic approved or in clinical trials (Table 2), with mechanisms of action that 
are not inconsistent with potential for efficacy in osteoarthritis, based on eQTL, functional genomics, 
rare disease and animal model data. Four of these genes, TGFB1, GDF5, FGF18 and CTSK, currently 
have therapeutics in clinical development for osteoarthritis/cartilage regeneration indications. Of 
these, only GDF5 has been previously published as genetically associated with osteoarthritis 
susceptibility9. Two of the genes, IL11 and DPEP1, have approved therapeutics for unrelated 
indications, opening the possibility for repositioning.  
 
rs4252548 (hip osteoarthritis, posterior probability of causality [PPC] 0.99), is a predicted deleterious 
missense variant (Arg112His) in IL11 (interleukin 11), associated with increased risk of hip 
osteoarthritis. Using RNA sequencing (Online Methods), we find that IL11 shows increased 
expression in degraded compared to intact cartilage (log2 fold change [logFC]=0.787, false discovery 
rate [FDR]=4.82x10-3). This cytokine is a potent stimulator of bone formation10, is required for 
normal bone turnover11 and has been previously found to be up-regulated in osteoarthritis knee 
tissue and to be associated with disease progression12. The rs4252548 osteoarthritis risk allele is also 
associated with decreased adult height13. A recombinant human IL11 molecule (NEUMEGA) with 
three-fold-enhanced affinity for IL11RA, compared to IL1114, is approved for the treatment of 
chemotherapy-induced thrombocytopenia (Table 2). The likely effects of increased IL11 signalling in 
osteoarthritis joints are currently not well understood, and it is worth evaluating this therapeutic for 
potential efficacy in disease models. 
 
The rs1126464 (osteoarthritis, PPC 0.89) locus index signal is a missense variant (Glu351Gln) in 
DPEP1, predicted to be tolerated. DPEP1 hydrolyses a wide range of dipeptides, and is implicated in 
the renal metabolism of glutathione and its conjugates. A DPEP1 inhibitor, cilastatin, is approved and 
used in combination with the antibiotic imipenem, in order to protect it from dehydropeptidase and 
prolong its antibacterial effect15. We suggest investigating the effects of cilastatin in osteoarthritis 
models to determine whether this has potential as a therapeutic, or whether an agonist may be 
efficacious. 
 
rs75621460 (hip and/or knee osteoarthritis, single variant in the 95% credible set) is an intergenic 
variant residing downstream of CCDC97 and TGFB1 (Table 1), and is colocalised with a TGFB1 eQTL in 
sun-exposed skin (GTEx) (Supplementary Table 6). Mutations in TGFB1 cause Camurati–Engelmann 
disease characterised by diaphyseal dysplasia with thickening and fluctuating bone volume giving 
rise to bone pain, muscle weakness, gait issues and tiredness16,17. TGFB1 plays a critical role in 
skeletal development and adult bone homeostasis18, including bone remodelling19, 
osteoclast/osteoblast differentiation20,21 and chondrogenesis22. INVOSSATM, a TGFB1 cell and gene 
therapy in chondrocytes, was associated with significant improvements in function and pain in 
patients with knee osteoarthritis23. 
 
The importance of TGFB1 signalling for osteoarthritis is supported by significant enrichment for “TGF 
Beta Signalling Pathway” genes (Supplementary table 9), including: LTBP1, LTBP3, SMAD3 and 
RUNX2. LTBP1, at the novel rs4671010 locus, directly interacts with TGFB1, is involved in the 
assembly, secretion and targeting of TGFB1 to sites at which it is stored and/or activated, and may 
contribute to controlling the activity of TGFB124. LTBP3 (novel locus: rs10896015) directly interacts 
with and activates TGFB1 in the early proliferative phase of osteogenic differentiation25. SMAD3 
(known locus: rs12901372) plays a critical role in chondrogenic differentiation, and regulates TGFB1 
expression26; and the TGFB1/SMAD3 pathway regulates the expression of miR-140 in 
osteoarthritis27. The directionality of the colocalized eQTL and animal model data suggest that 
agonism/up-regulation of LTBP1, LTBP3 and SMAD3 may be therapeutic for osteoarthritis 
(Supplementary Table 20). RUNX2 (known locus: rs2064630) is a transcription factor essential for the 
osteoblast differentiation and chondrocyte maturation28, and is down-regulated by TGFB129. Given 
the genetic and biological support for the importance of TGFB1 in osteoarthritis aetiology and 
treatment, there may be scope for the development of simpler osteoarthritis therapeutics which 
target this mechanism, such as a small molecule or antibody. 
 
Although not a current drug target, the novel SLC39A8 association is noteworthy. rs13107325 
(osteoarthritis, PPC 0.99) is a missense variant located in SLC39A8 and demonstrates significantly 
increased expression in degraded compared to intact articular cartilage (logFC=0.522, FDR=5.80x10-
5) (Table1; Supplementary Table 2), consistent with previously-reported increased levels of SLC39A8  
in osteoarthritis compared to healthy chondrocytes30,31. rs13107325 is also associated with obesity32, 
hypertension33, Crohn's disease and altered microbiome composition34. SLC39A8 functions in the 
cellular import of zinc at the onset of inflammation. Suppression of SLC39A8 has been shown to 
reduce cartilage degradation in osteoarthritis animal models30. The zinc- SLC39A8-MTF1 axis has 
been proposed to be an essential catabolic regulator of osteoarthritis pathogenesis31.  
 
In this study, we have more than doubled the number of osteoarthritis risk loci, supported by 
integrated eQTL colocalization, fine-mapping, Mendelian bone disease, animal model and 
differential osteoarthritis joint expression data, to reveal putative effector genes. In addition to 
identifying chondrocyte and osteoblast biological mechanisms implicated in osteoarthritis 
susceptibility, we have revealed biological mechanisms that represent attractive targets for 
osteoarthritis drug discovery, and highlight approved therapeutics which represent viable 
considerations for repositioning as osteoarthritis therapies. We anticipate that this advance in basic 
understanding of osteoarthritis risk factors and mechanisms will stimulate the evaluation of novel 
drug targets for osteoarthritis. 
  
 
 
  
ONLINE METHODS 
 
Studies  
UK Biobank: UK Biobank is a cohort of 500,000 participants aged 40-69 years recruited between 
2006 and 2010 in 22 assessment centres throughout the UK35. The assessment visit included 
electronic signed consent; a self-completed touch-screen questionnaire; brief computer-assisted 
interview; physical and functional measures; and collection of biological samples and genetic data. 
This work was based on the third UK Biobank release, which includes the full set of the 500,000 
genotypes imputed on the Haplotype Reference Consortium36 and the 1000 Genomes Consortium37. 
Briefly, 50,000 samples were genotyped using the UKBiLEVE array and the remaining samples were 
genotyped using the UK Biobank Axiom array (Affymetrix). After sample and SNP quality control (QC) 
of the directly-typed genotypes, followed by phasing and imputation, carried out centrally38, there 
are approximately 97million variants in 487,411 individuals. Following additional QC checks, we 
excluded samples with call rate ≤95%. We checked samples for gender discrepancies, excess 
heterozygosity, over third degree relatedness, ethnicity and we removed possibly contaminated and 
withdrawn samples. Variants with minor allele frequency (MAF) of ≤0.1% or effective minor allele 
count (imputation quality score times minor allele count) ≤90 were discarded. In summary, we 
interrogated approximately 17 million variants from 450,805 related individuals of European descent 
(Supplementary Figure 1). 
 
To define osteoarthritis cases, we used the self-reported status established during interview with a 
nurse (Field 20002; Initial assessment visit) and the Hospital Episode Statistics ICD10 primary and 
secondary codes. We conducted four osteoarthritis discovery GWAS: self-reported or hospital-
diagnosed osteoarthritis at any site based on ICD10 hospital record codes M15-M19 (n=70,532); 
hospital-diagnosed hip osteoarthritis based on ICD10 hospital record M16 (n=12,850); hospital-
diagnosed knee osteoarthritis based on ICD10 hospital record M17 codes (n=21,921); and hospital-
diagnosed hip and/or knee osteoarthritis (M16 or M17; n=32,907). To minimise misclassification in 
the control datasets to the extent possible, in all analyses, from the controls, we excluded individuals 
with primary or secondary ICD10 codes M05 through M14, as well as arthrosis codes M15-M19. This 
excluded individuals with inflammatory polyarthropathies and resulted in a control sample size of 
369,983 controls (Supplementary Figure 1). 
 
Principle components (PCs) were computed using fastPCA39 and high quality directly typed markers 
from the unrelated set of Europeans. PCs were then projected to the related European sample using 
SNP weights. We tested for association using the non-infinitesimal mixed model association test 
implemented in BOLT-LMM v2.340 with adjustment for the first 10 PCs, sex, age at recruitment and 
genotyping chip. As BOLT-LMM implements a linear regression, effect size estimates and their 
standard errors for case-control outcomes have been calculated by dividing the effect size estimates 
and standard errors output by the software by 𝑝 ×  (1 − 𝑝), where 𝑝 is the proportion of cases in 
the trait definition41. 
 
Arthritis Research UK Osteoarthritis Genetics (arcOGEN) – cases: arcOGEN is a collection of 
unrelated, UK-based individuals of European ancestry with knee and/or hip osteoarthritis from the 
arcOGEN Consortium9,42. Cases were ascertained based on clinical evidence of disease to a level 
requiring joint replacement or radiographic evidence of disease (Kellgren–Lawrence grade ≥2). The 
arcOGEN study was ethically approved, and all subjects used in this study provided written, informed 
consent. 
United Kingdom Household Longitudinal Study (UKHLS) – controls: The UKHLS, also known as 
Understanding Society, is a longitudinal panel survey of 40,000 UK households (England, Scotland, 
Wales and Northern Ireland) representative of the UK population. Participants are surveyed 
annually since 2009 and contribute information relating to their socioeconomic circumstances, 
attitudes, and behaviours via a computer assisted interview. The study includes phenotypical data 
for a representative sample of participants for a wide range of social and economic indicators as well 
as a biological sample collection encompassing biometric, physiological, biochemical, and 
haematological measurements and self-reported medical history and medication use. The UKHLS has 
been approved by the University of Essex Ethics Committee and informed consent was obtained 
from every participant. 
Genotyping, imputation and association testing: 7,410 arcOGEN cases were genotyped on the 
Illumina Human 610-Quad array, 670 arcOGEN cases were genotyped on the Illumina OmniExpress 
array, and 9,296 UKHLS controls were genotyped on the Illumina CoreExome array. Genotype QC has 
been previously described9,43,44. Prior to imputation all variants were mapped to GRCh37 and cases 
and controls were merged into a single dataset containing overlapping variants. We further excluded 
variants with MAF≤1, indels, and evidence for differential missingness between cases and controls 
(Fisher’s exact test P<0.0001). We performed a case-control analysis and visually inspected the 
cluster plots for any variant with P≤5x10-8; variants with poor clusters were excluded. Final QC 
checks prior to imputation were performed using a HRC pre-imputation checking tool (URLs). 
Imputation was performed on 17,376 individuals and 126,188 variants using the Michigan HRC36,45 
imputation server with Eagle246 for the prephasing. We excluded related individuals by performing 
pair-wise identity-by-descent (IBD) (using PI_HAT threshold > 0.2) in PLINK47 using directly typed 
variants with MAF>1% and pruned for LD using r2<0.2. In addition, we excluded any individuals that 
were related to individuals in the UK Biobank dataset using the imputed variants and the same IBD 
method as described above. We also excluded any variant that had an imputation information score 
(minimac R-square)<0.3, with a Hardy Weinberg P≤1x10-6 and MAF ≤ 0.1%The final dataset 
contained ~11.6 million variants in 6,520 cases and 8,186 controls. Association analysis was 
performed using SNPTEST48 with the first ten principal components as covariates.  The arcOGEN 
dataset comprised three osteoarthritis phenotypes: hip osteoarthritis (2,854 cases and 8,186 
controls), knee osteoarthritis (3,034 cases and 8,186 controls), and hip and/or knee osteoarthritis 
(6,520 cases and 8,186 controls). 
 
Meta-analysis 
We meta-analysed the UK Biobank and arcOGEN  datasets using fixed effects inverse-variance 
weighted meta-analysis in METAL49. We performed meta-analyses across osteoarthritis definitions 
using summary statistics from the UK Biobank and arcOGEN cohorts, and defined genome-wide 
significance based on the meta-analysis combined P value as outlined below.  
 
Significance threshold 
The osteoarthritis traits analysed in this study are highly correlated. To calculate 𝑀_𝑒𝑓𝑓 the effective 
number of independent traits, we estimated the genetic correlation matrix between the 4 
osteoarthritis traits (Supplementary Table 1) using LDscore50 with genome-wide summary statistics of 
common-frequency variants in the UK Biobank dataset. We then calculated 𝑀_𝑒𝑓𝑓 from the 
eigenvalues 𝜆_𝑖  of the correlation matrix51: 
 
𝑀] 
 
𝑀𝑒𝑓𝑓 = 𝑀 −  ∑[𝐼(𝜆𝑖 > 1)(𝜆𝑖 − 1)]
𝑀
𝑖=1
 
 
For the 𝑀 = 4 osteoarthritis phenotypes in this study, 𝑀_𝑒𝑓𝑓 = 1.6046. We therefore use P≤3x10-8 
as the threshold corrected for the effective number of traits to report genome wide significance. 
 
Statistical independence 
To define independent signals within a GWAS, we performed physical clumping using a simple 
iterative procedure. We rank all variants that reach a P value threshold according to their P value. 
The variant with the smallest P value is considered the index variant of that signal and any variants 
within 1MB region either side of that index variant that reach the pre-defined P value threshold are 
clumped with that variant. We repeat the procedure until no more variants that reach the pre-
defined P value threshold exist that have not been assigned to a physical clump. To test that the 
index variants defined by this procedure are statistically independent, we performed an 
approximate stepwise model selection procedure, as implemented by COJO in GCTA7. An 
independent signal in a region is declared if its P value of association in the stepwise regression is 
less than 3x10-8. LD calculations were based on the full UK Biobank imputed set. 
 
To define independent signals across the four osteoarthritis GWAS, we performed reciprocal 
approximate conditional analyses, as implemented by COJO in GCTA7, of each index variant of one 
GWAS conditioned on each index variant of the other GWAS. A signal between two GWAS is 
considered to be the same if the P value of an index variant of one GWAS conditioned on an index 
variant of the other GWAS is ≤ 10-5 or a P value difference between conditional and unconditional 
analysis of less than 2 orders of magnitude. 
 
To investigate statistical independence between index variants from each GWAS and previously 
reported variants, we performed approximate conditional analysis, as implemented by COJO in 
GCTA7, of each index variant conditional on all previously reported variants within 1Mb region, each 
one at a time. The index variant was considered independent from a previously reported variant if it 
had a conditional P ≤ 10-5 or a P value difference between conditional and unconditional analysis of 
less than 2 orders of magnitude. Variants were classified as known (denoting either a previously 
reported variant, or a variant for which the association signal disappears after conditioning on the 
lead variant of a previously reported locus) or newly identified (denoting a variant which is 
conditionally independent of previously reported loci).  
 
Fine-mapping 
We constructed regions for fine-mapping by taking a window of 1Mb either side of each index 
variant. Within each region, we performed an approximate stepwise model selection procedure, as 
implemented by COJO in GCTA7, using the meta-analysis summary statistics and LD calculations 
based on the UK Biobank cohort to determine the number of independent signals. We consider 
conditionally distinct signals those where the stepwise regression association reaches genome-wide 
significance (P<3.0x10-8).  We then perform single-SNP approximate association analyses conditional 
on the set of SNPs identified by the model selection procedure, again using COJO, and we calculate 
Wakefield’s asymptotic Bayes’ factors8 (ABF). In particular, when there is a single causal variant in 
the region, ABF is based on the marginal summary statistics of the meta-analysis. When there are 
multiple causal variants in the region, for each signal we calculate a set of ABF using the conditional 
summary statistics of the meta-analysis conditioned on all other signals. For each signal, we then 
calculate posterior probabilities of each variant being causal and a 95% credible set, which contains 
the minimum set of variants that jointly have at least 95% probability of including the causal variant. 
As this number can be large, we focus on the variants in the 95% credible set that have posterior 
probability of causality (PPC) over 3% and also on any variants in the 95% credible set with moderate 
or high consequence (irrespective of their PPC).  
 
Genetic correlation analysis 
To better understand the degree to which genetic architecture is shared across osteoarthritis and 
other complex traits, LD score regression5  was performed as implemented in the LDHub pipeline6 
(URLs). We calculated the genome-wide genetic correlation between each of the osteoarthritis 
definitions and all available 832 human traits and diseases (accessed 15-18 June 2018). Of these, 597 
traits were available within the UK Biobank resource. In each analysis, all variants in the major 
histocompatibility complex (MHC) region on chromosome 6 (26–34 MB) were removed and only 
variants with rsIDs were included in the analyses, yielding 1203892 - 1204029 variants overlapping 
with LDHub. We used the Benjamini-Hochberg false discovery rate and the effective number of 
independent traits tested for multiple testing correction. The level of significance was set at FDR-
corrected P<0.05. 
 
Mendelian randomization 
We performed Mendelian randomization analyses using the MR-Base platform52. We tested the 
bidirectional causal associations of each of the four osteoarthritis datasets with 991 exposures/ 
outcomes in MR-Base. Statistical significance was considered at P<6.3x10-6. To follow up on pain 
associations, we performed analyses of knee and hip pain as an outcome after excluding all 
individuals self-reporting or hospital-diagnosed with osteoarthritis in UK Biobank. All instruments 
were aggressively clumped prior to analysis (LD r2<0.001) and inverse variance-weighted (IVW), 
Median-weighted, and MR-Egger analyses were performed for multi-variant instruments, and Wald 
ratio estimators were used to assess causality for single variant instruments.  
 
Transcriptome-wide association  
We used a gene-based approach, MetaXcan53, to test for associations between the osteoarthritis 
traits and predicted expression levels in 48 human tissues from GTEx V754. MetaXcan leverages a set 
of reference individuals for whom both gene expression and genetic variation have been measured 
to impute the cis-genetic component of expression into a much larger set using the elastic net 
model. It then correlates the imputed gene expression to the trait of interest and performs a 
transcriptome-wide association study to identify significant expression-trait associations. We used a 
conservative Bonferroni correction to account for the gene-tissue pairs (20,000 genes across 48 
tissues), leading to a significance threshold of 5.20x10-8. To reduce the effect of LD confounding on 
the MetaXcan results, when different causal SNPs are affecting expression levels and the phenotypic 
trait in a GWAS, we estimated the probability of colocalization of each GWAS and expression 
quantitative trait locus (eQTL) signal in each significant MetaXcan result using Coloc55 
(Supplementary Note; Supplementary Tables 7-8; Supplementary Figure 7).  
 
Colocalization analysis 
To assess whether the genome-wide significant osteoarthritis signals colocalise with eQTL signals, 
and therefore potentially share a causal molecular mechanism, we employed the Coloc method55, 
which uses asymptotic Bayes factors with summary statistics and regional LD structure to estimate 
five posterior probabilities: no association with either GWAS or eQTL (PP0), association with GWAS 
only (PP1), association with eQTL only (PP2), association with GWAS and eQTL but two independent 
SNPs (PP3), and association with GWAS and eQTL having one shared SNP (PP4). A large posterior 
probability for PP4 indicates support for a single variant affecting both GWAS and eQTL studies. For 
each of the GWAS signals, we defined a 100kb region either side of the index variant, and tested for 
colocalization within the entire cis-region of any overlapping eQTLs (transcription start and end 
position of an eQTL gene plus and/or minus 1Mb, as defined by GTEx) in 48 human tissues from 
GTEx V754. A PP4 over or equal to 80% was considered as evidence for colocalization (Supplementary 
Note; Supplementary Table 6). 
 
Most colocalization methods, such as Coloc, rely on the availability of genome-wide eQTL results, 
which are not always readily available. For eQTL datasets with no publically available full summary 
statistics, we used an alternative approach that estimates the probability of colocalization using 
published top eQTL signals. First, we estimated the credible sets for the eQTLs using the Probabilistic 
Identification of Causal SNPs (PICS) method56 for each index SNP for each gene from 27 eQTL studies 
(Supplementary Table 5). PICS is a fine-mapping algorithm that assumes one causal signal tagged by 
a single index SNP per locus.  For neutral SNPs (SNPs whose association signals are due to LD with 
the causal SNP), the strength of association scales linearly with the r2 relationship/distance to the 
index SNP.  Under this assumption, PICS can estimate the posterior probability of a given SNP being 
causal using LD information from the 1000 Genomes database. Second, we generated PICs credible 
sets for osteoarthritis GWAS index SNPs. We then performed a colocalization analysis of the 
osteoarthritis GWAS and eQTL PICs credible sets using an adapted Coloc method50.  Given that PICs 
calculates the posterior probabilities for each SNP in the credible set, we bypassed the need for 
calculating the Bayes Factors using Wakefield’s approximate Bayes Factor method which is reliant on 
full summary statistics. Colocalizations with a posterior probability greater than 0.8 were considered 
positive. This method was benchmarked on other GWAS datasets, and we found the false positive 
rate to be no higher than the standard Coloc package.  
 
We observe evidence of colocalization in at least one tissue for 50 out of our 64 loci using any of the 
3 methods (MetaXcan, Coloc, Piccolo), 41 of which are at newly associated osteoarthritis signals 
(Supplementary Table 6). MetaXcan alone identified 119 genes, Coloc 113 and Piccolo 58, while the 
overlap of all 3 methods implicate 20 genes (TGFA, ILF3, CSK, CYP1A1, ULK3, CHMP1A, TSKU, 
SUPT3H, GNL3, NT5DC2, LMX1B, SMAD3, MLXIP, COLGALT2, FAM89B, UQCC1, NFAT5, ALDH1A2, 
FAM53A, FGFR3; Supplementary Figure 9). 
 
Heritability estimation 
To investigate the narrow sense heritability for the four osteoarthritis disease definitions, we ran 
LDscore50, which uses summary statistics at common-frequency variants genome-wide (independent 
of P value thresholds) and LD estimates between variants while accounting for sample overlap. To 
calculate the population prevalence in the UK (65 million people), we consulted Arthritis Research 
UK figures: 8.75 million people have symptomatic osteoarthritis, while 2.46 and 4.11 million people 
have osteoarthritis of the hip and the knee, respectively. We assumed that 2.46+4.11 million people 
have osteoarthritis of the hip and/or the knee. We estimated the phenotypic variance explained by 
the 99previously and newly reported variants that reached genome-wide significance in the meta-
analysis between UK Biobank and arcOGEN, as a function of allele frequency (Figure 2; 
Supplementary Table 18). The phenotypic variance explained by a variant is ) 𝑙𝑛(𝑂𝑅)2 × 2 × 𝐸𝐴𝐹 ×
(1 − 𝐸𝐴𝐹), where ln(𝑂𝑅) is the natural logarithm of the OR of the variant in the meta-analysis and 
𝐸𝐴𝐹 is its weighted effect allele frequency across UK Biobank and arcOGEN. Variants associated with 
hip osteoarthritis tend to have larger effect size estimates and hence explain more of the phenotypic 
variability (Figure 2; Supplementary Table 18). The hip osteoarthritis dataset is the smallest in both 
the UK Biobank and arcOGEN cohorts (18% and 59% fewer cases compared to knee osteoarthritis 
and osteoarthritis at any joint in UK Biobank, respectively). 
 
Pathway analysis 
We performed gene-set analyses for each of the osteoarthritis phenotypes separately, using 
MAGMA v1.0657. We mapped variants to 19,427 protein-coding genes (NCBI 37.3), including a 10kb 
window on either side of the gene. We then computed gene P values based on individual variant 
association P values. We used the ‘snp-wise=mean’ model, which calculates the mean of the χ2-
statistic amongst the single variant P values in each gene, and applied default MAGMA QC steps. 
Genotype data of 10,000 individuals (subset of self-reported plus hospital-diagnosed osteoarthritis 
at any site analysis), were used to calculate LD (as measured by r2). We carried out a one-sided 
competitive gene-set analysis for each phenotype, implemented as a linear regression model on a 
gene data matrix created internally from the gene-based results. Briefly, this converts the gene-
based P values to Z-scores, and tests if the mean association with the phenotype of genes in the 
gene set is greater than that of all other genes. We used Kyoto Encyclopedia of Genes and Reactome 
(accessed through MSigDB113 (version 5.2) on 23 January 2017). We also downloaded Gene 
Ontology (GO) biological process and molecular function gene annotations from Ensembl (version 
87). We used annotations with the following evidence codes: a) Inferred from Mutant Phenotype 
(IMP); b) Inferred from Physical Interaction (IPI); c) Inferred from Direct Assay (IDA); d) Inferred from 
Expression Pattern (IEP); and e) Traceable Author Statement (TAS). KEGG/Reactome and GO 
annotations were analysed separately and only pathways that contained between 20 and 200 genes 
were included (594 for KEGG/Reactome, 619 for GO). We used MAGMA’s built-in permutation 
method (k=10,000 permutations) to produce corrected competitive P values with a family-wise error 
rate (FWER) of 5%. We then further adjusted these corrected competitive P values for the effective 
number of independent traits tested (1.6046). 
 
We also performed gene set enrichment analysis by using DEPICT (URLs) and PASCAL (URLs). DEPICT 
version 1 rel194 was downloaded from GitHub (URLs) on 14/06/2018. We run DEPICT separately in 
each of the four osteoarthritis definitions for the variants with a meta-analysis P<1x10-5. Briefly, 
DEPICT first clumped the variants with P<1x10-5 using 500 kb flanking regions as physical distance 
threshold and an r2>0.1 with PLINK47 to obtain lists of independent SNPs, resulting in 864 clumps. 
Variants within the major histocompatibility complex region on chromosome 6 were excluded. 
DEPICT analyses were conducted using the default settings: 50 repetitions to compute FDR and 500 
permutations based on 500 null GWAS to compute P values adjusted for gene length. All 14,461 
available reconstituted gene sets were used representing a wide spectrum of biological and mouse 
phenotypic annotations. We also used the method implemented in PASCAL to perform gene set 
enrichment analysis which accounts for LD structure in the genome and particularly of highly 
correlated chromosomal regions containing multiple genes that can negatively impact the results of 
the analysis. In this approach, variants were first mapped to genes, including a 10kb window on 
either side of the gene. We then computed gene scores by aggregating the single-marker association 
values with the LD structure. Finally, the scores of genes that belong to the same pathways (i.e. gene 
sets) were used to compute pathway scores and determine the statistical significance of the 
association between the pathway and each of the osteoarthritis phenotypes. Here we used exactly 
the same pathways of the MAGMA analysis. The gene and the pathway scores were performed by 
using the sum gene score and the chi-squared approach respectively, as implemented in PASCAL. All 
pathway P values obtained by either software were adjusted for multiple testing correction by using 
FDR and the effective number of independent traits. The level of significance was set at FDR-
corrected P<0.05. 
 
Monogenic enrichment analysis 
We compiled a systematic list of genes causing bone phenotypes in humans by scanning the 
STOPGAP database53, which uses OMIM (URLs) and Orphanet (URLs) to define genes underlying 
monogenic/Mendelian diseases. We selected all genes causing monogenic diseases and annotated 
with MeSH terms (Medical Subject Headings) related to bone, cartilage or joint disease, including: 
“bone disease, developmental”, “osteochondrodysplasias”, “osteogenesis imperfecta”, 
“osteoporosis”, “osteopetrosis”, “arthritis, juvenile” and “arthrogryposis”. Other bone-, cartilage or 
joint related mesh terms linked to less than 10 genes in the STOPGAP database were excluded from 
the analysis. Additionally, we selected a list of well-validated genes underlying syndromic or non-
syndromic forms of early onset osteoarthritis (EO-OA) from a review by Aury-Landas et al.54. For 
enrichment analysis, genes residing within 500kb of each index variant identified in our GWAS were 
considered as osteoarthritis loci, and the rest of the genes in the genome associated to any mesh 
term in STOPGAP were considered non-osteoarthritis loci. We built a 2x2 table by counting the 
number of genes annotated to each of the above-mentioned MeSH terms among osteoarthritis and 
non-osteoarthritis loci. We assessed evidence for enrichment using a Fisher’s exact test.  
 
Transcriptomic and proteomic analyses 
Patients and samples: We collected cartilage samples from 38 patients undergoing total joint 
replacement surgery: 12 knee osteoarthritis patients (cohort 1; 2 women, 10 men, age 50-88 years); 
knee osteoarthritis patients (cohort 2; 12 women 5 men, age 54-82 years); 9 hip osteoarthritis 
patients (cohort 3; 6 women, 3 men, age 44-84 years). We collected matched intact and degraded 
cartilage samples from each patient. Cartilage was separated from bone and chondrocytes were 
extracted from each sample. From each isolated chondrocyte sample, we extracted DNA, RNA and 
protein. All patients provided full written informed consent prior to participation. The human 
biological samples were sourced ethically and their research use was in accord with the terms of the 
informed consents under an IRB/EC approved protocol. All sample collection, DNA, RNA and protein 
analysis steps are described in detail in Steinberg et al58. 
 
Proteomics: Proteomics analysis was performed on intact and degraded cartilage samples from 24 
individuals (15 from cohort 2, 9 from cohort 3). LC-MS analysis was performed on the Dionex 
Ultimate 3000 UHPLC system coupled with the Orbitrap Fusion Tribrid Mass Spectrometer. To 
account for protein loading, abundance values were normalised by the sum of all protein 
abundances in a given sample, then log2-transformed and quantile normalised. We restricted the 
analysis to 3917 proteins that were quantified in all samples. We tested proteins for differential 
abundance using limma59 in R, based on a within-individual paired sample design. Significance was 
defined at 1% Benjamini-Hochberg FDR to correct for multiple testing. Of the 3732 proteins with 
unique mapping of gene name and Ensembl ID, we took forward 245 and 489 proteins with 
significantly different abundance between intact and degraded cartilage at 1% and 5% FDR, 
respectively (Supplementary table 2). 
 
RNA sequencing: We performed a gene expression analysis on samples from all 38 patients. 
Multiplexed libraries were sequenced on the Illumina HiSeq 2000 (75bp paired-end read length). 
This yielded bam files for cohort 1 and cram files for cohorts 2 and 3. The cram files were converted 
to bam files using samtools 1.3.160 and then to fastq files using biobambam 0.0.19161, after exclusion 
of reads that failed QC. We obtained transcript-level quantification using salmon 0.8.262 (with --
gcBias and --seqBias flags to account for potential biases) and the GRCh38 cDNA assembly release 87 
downloaded from Ensembl. We converted transcript-level to gene-level count estimates, with 
estimates for 39037 genes based on Ensembl gene IDs. After QC, we retained expression estimates 
for 15994 genes with counts per million of 1 or higher in at least 10 samples. Limma-voom63 was 
used to remove heteroscedasticity from the estimated expression data. We tested genes for 
differential expression using limma in R (with lmFit and eBayes), based on a within-individual paired 
sample design. Significance was defined at 1% Benjamini-Hochberg FDR to correct for multiple 
testing. Of the 14408 genes with unique mapping of gene name and Ensembl ID, we took forward 
1705 genes with significantly different abundance between intact and degraded cartilage at 1% FDR. 
 
Animal model data 
The presence of abnormal skeletal phenotypes in mice was evaluated for all genes within 500kb of 
an osteoarthritis index variant and extracted from Open Targets64. This platform integrates all 
abnormal phenotype annotations for mutations in mouse genes reported in the literature and 
curated at MGI (URLs). Given the list of genes located less than 1 Mb away of the 64 genome-wide 
significant signals for osteoarthritis, abnormal skeletal system phenotypes from mutant mice were 
extracted systematically for all mouse orthologs of the human genes using the programmatic 
interface of the Open Targets platform (Supplementary Table 20). For instance, mutant mice 
homozygous for a targeted mutation of Smad3 (the ortholog of human SMAD family member 3) 
developed degenerative joint disease by progressive loss of articular cartilage65. Additional manual 
PubMed searches were conducted on selected genes to obtain information regarding animal models 
specific for osteoarthritis (Supplementary Table 19). 
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EGAD00001001331; cohort 2: EGAD00001003355; cohort 3: EGAD00001003354). Genotype data of 
the arcOGEN cases and UKHLS controls have been deposited at the European Genome-phenome 
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http://www.orpha.net/; HRC pre-imputation checking tool, 
http://www.well.ox.ac.uk/~wrayner/tools/#Checking; MGI, http://www.informatics.jax.org; Open 
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https://www.understandingsociety.ac.uk/; DEPICT, www.broadinstitute.org/depict; PASCAL 
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Figure 1: Genetic correlations between osteoarthritis and other traits and diseases. Genetic 
correlations (rg) between osteoarthritis and other publicly available GWAS results, based on LD 
score regression as implemented in LDHub. The diagram shows traits with significant correlation 
(P<0.05) and 95% confidence intervals across all osteoarthritis definitions. The red outline of the 
bars denotes negative correlation and the blue outline denotes positive correlation. The upper right 
legend shows the categories of the traits. OA: osteoarthritis; OA_hip: Hip osteoarthritis; OA_knee: 
Knee osteoarthritis; OA_kneehip: Knee and/or hip osteoarthritis. Lumbar spine bone mineral density 
1 and 2 relate to two different published studies. 
 
Figure 2: Allelic architecture of index variants. Meta-analysis based odds ratio with its 95% 
confidence interval of 99 variants (previously-reported denoted as circles and newly-reported 
denoted as diamonds) with UK Biobank and arcOGEN meta-analysis P<3.0x10-8 (two-sided) as a 
function of their weighted allele frequency. The curves indicate 80% power at the genome-wide 
significance threshold of P≤3.0x10-8, for the four sample sizes of the meta-analyses. We have 80% 
power to detect an association at genome-wide significance for a variant with 1% MAF and allelic 
odds ratio of 1.19, 1.40, 1.32 and 1.25 for all osteoarthritis, hip osteoarthritis, knee osteoarthritis 
and knee and/or hip osteoarthritis, respectively. For 0.1% MAF the corresponding odds ratios are 
1.66, 2.43, 2.12 and 1.90. 
  
Table 1: Independent variants with P<3x10-8 in an inverse-variance weighted fixed effects meta-analysis of UK Biobank and arcOGEN. Variant positions 
are reported according to build 37 and their alleles are coded based on the positive strand.  
 
SNPID RSID 
Most 
Severe 
Conseq
uence 
Trait 
Other 
Traits 
GWAS 
sign meta-
analysis 
EA 
NE
A 
UK Biobank arcOGEN 
WEAF OR 
OR_L
95 
OR_U95 PV q_pv i2 
EAF 
OR PV OR PV 
Cases/Controls
*  
1000 
Genomes 
GBR ** 
                          
Newly Identified Loci                          
1:103572927 rs4338381 
sequenc
e_featu
re 
OA_hip 
OA;OA_kn
eehip 
A G 1.1 4.70E-13 1.1 2.71E-03 0.63 1.1 1.07 1.13 4.37E-15 0.93 0 
0.6529/0.6307           
0.654/0.6316 
0.62                                              
(0.55, 0.69)      
1:150214028 1:150214028 
downstr
eam_ge
ne 
OA OA_hip C CT 1.03 2.50E-08     0.37 1.03 1.02 1.05 2.54E-08 1 0 
0.3679/0.36                    
- 
- 
1:174192402 1:174192402 intron OA  
TAAAAA
AAAAA
AAAAA
AA 
T 1.03 1.10E-08     0.57 1.03 1.02 1.05 1.05E-08 1 0 
0.5855/0.5758           
- 
- 
1:183906245 rs11583641 
3_prime
_UTR 
OA_hip  C T 1.09 3.10E-09 1.07 5.55E-02 0.72 1.08 1.06 1.11 5.58E-10 0.63 0 
0.7404/0.7246           
0.7347/0.7218 
0.68                                              
(0.61, 0.74)      
1:245750932 rs10218792 intron OA  G T 1.04 7.40E-08 1.04 5.13E-02 0.27 1.04 1.02 1.05 2.03E-08 0.77 0 
0.2739/0.2675           
0.274/0.2656 
0.2                                              
(0.15, 0.27)      
2:33434336 rs2061027 intron OA 
OA_knee;
OA_kneeh
ip 
A G 1.04 9.70E-12 1.07 6.58E-03 0.51 1.04 1.03 1.05 3.16E-13 0.25 
25.
8 
0.5141/0.5041           
0.5178/0.5011 
0.55                                              
(0.47, 0.62)      
2:192671981 rs12470967 intron 
OA_kne
e 
OA_kneeh
ip 
A G 1.06 1.50E-08     0.43 1.06 1.04 1.08 1.50E-08 1 0 
0.4416/0.4291           
- 
0.55                                              
(0.48, 0.63)      
2:204387482 rs62182810 intron OA  A G 1.03 6.20E-09 1.04 5.44E-02 0.55 1.03 1.02 1.05 1.65E-09 0.84 0 
0.554/0.5462           
0.5562/0.5468 
0.52                                              
(0.45, 0.6)      
3:50022049 rs62262139 intron OA  A G 1.04 9.10E-11     0.54 1.04 1.03 1.05 9.09E-11 1 0 
0.544/0.5348                
- 
0.54                                              
(0.47, 0.62)      
4:1704244 rs11732213 intron 
OA_kne
ehip 
OA;OA_hi
p 
T C 1.06 2.30E-09 1.04 1.46E-01 0.81 1.06 1.04 1.08 8.81E-10 0.6 0 
0.8142/0.8047           
0.8159/0.8092 
0.73                                              
(0.66, 0.79)      
4:13039440 rs1913707 
interge
nic_regi
on 
OA_hip OA A G 1.07 9.00E-08 1.16 4.24E-06 0.61 1.08 1.06 1.11 2.96E-11 0.03 79 
0.6271/0.6111           
0.6421/0.6083 
0.59                                              
(0.52, 0.66)      
4:25408838 rs34811474 
missens
e 
OA  G A 1.04 3.70E-09 1.03 1.93E-01 0.77 1.04 1.03 1.05 2.17E-09 0.76 0 
0.7745/0.7671           
0.7873/0.7821 
0.71                                              
(0.64, 0.77)      
4:103188709 rs13107325 
missens
e 
OA  T C 1.1 4.10E-18 1.08 5.14E-02 0.08 1.1 1.07 1.12 8.29E-19 0.7 0 
0.0801/0.0735           
0.0871/0.0811 
0.1                                              
(0.06, 0.15)      
5:77467824 rs35611929 intron 
OA_kne
e 
 A G 1.06 5.50E-08 1.06 7.93E-02 0.34 1.06 1.04 1.08 1.21E-08 0.96 0 
0.3544/0.3411           
0.3418/0.3296 
0.32                                              
(0.25, 0.39)      
5:170871074 rs3884606 intron 
OA_kne
ehip 
 G A 1.04 2.10E-07 1.06 3.43E-03 0.49 1.04 1.03 1.06 8.25E-09 0.42 0 
0.498/0.4868           
0.4997/0.4843 
0.47                                              
(0.39, 0.54)      
6:26123502 rs115740542 
upstrea
m_gene 
OA 
OA_hip;O
A_kneehip 
C T 1.06 2.00E-08 1.06 6.72E-02 0.07 1.06 1.04 1.08 8.59E-09 0.95 0 
0.0776/0.0731           
0.0743/0.0704 
0.05                                              
(0.02, 0.09)      
6:33055501 rs9277552 
downstr
eam_ge
ne 
OA_kne
ehip 
OA_knee;
OA 
C T 1.06 9.30E-10 1.05 1.07E-01 0.79 1.06 1.04 1.08 2.37E-10 0.78 0 
0.7964/0.7862           
0.8246/0.8171 
0.7                                              
(0.62, 0.76)      
6:44449697 rs12154055 
interge
nic_regi
on 
OA  G A 1.03 6.90E-09 0.99 8.95E-01 0.61 1.03 1.02 1.04 2.71E-08 0.1 
63.
5 
0.6194/0.6117           
0.6112/0.613 
0.66                                              
(0.59, 0.73)      
6:55636940 rs80287694 intron OA_hip  G A 1.13 2.10E-09 1.05 2.64E-01 0.11 1.12 1.08 1.16 2.66E-09 0.2 
39.
1 
0.1246/0.1128           
0.1159/0.1107 
0.15                                              
(0.1, 0.22)      
7:95719833 rs11409738 intron OA 
OA_kneeh
ip 
TA T 1.04 2.10E-10     0.37 1.04 1.03 1.05 2.13E-10 1 0 
0.3751/0.3664           
- 
0.39                                              
(0.32, 0.47)      
8:9087679 rs330050 
upstrea
m_gene 
OA 
OA_kneeh
ip;OA_hip 
G C 1.04 2.90E-10 1.06 9.51E-01 0.51 1.04 1.03 1.05 1.93E-11 0.35 0 
0.5145/0.5052           
0.5141/0.4995 
0.45                                              
(0.37, 0.52)      
8:130768503 rs60890741 
upstrea
m_gene 
OA_hip  C CA 1.11 4.50E-09     0.86 1.11 1.08 1.16 4.50E-09 1 0 
0.8796/0.8671           
- 
0.87                                              
(0.81, 0.91)      
9:116911147 rs919642 
interge
nic_regi
on 
OA 
OA_kneeh
ip;OA_kne
e 
T A 1.05 1.10E-14 1.03 1.96E-01 0.27 1.05 1.04 1.06 8.55E-15 0.41 0 
0.2697/0.2595           
0.2774/0.2717 
0.27                                              
(0.21, 0.35)      
9:117840742 rs1330349 
upstrea
m_gene 
OA_hip  C G 1.08 2.40E-09 1.09 3.93E-03 0.58 1.08 1.06 1.11 4.10E-11 0.71 0 
0.5926/0.5738           
0.5988/0.5773 
0.6                                              
(0.53, 0.68)      
9:129386860 rs62578127 intron OA_hip  C T 1.09 2.00E-11 1.07 2.15E-02 0.63 1.09 1.06 1.11 2.77E-12 0.54 0 
0.6514/0.6307           
0.6552/0.6401 
0.6                                              
(0.52, 0.67)      
11:28874997 rs17659798 intron 
OA_kne
ehip 
 A C 1.05 2.50E-09 1.06 2.14E-02 0.71 1.06 1.04 1.07 2.06E-10 0.86 0 
0.725/0.7135           
0.7266/0.7149 
0.69                                              
(0.61, 0.75)      
11:30774280 rs11031191 
interge
nic_regi
on 
OA  T G 1.03 3.30E-08 1.03 9.65E-02 0.35 1.03 1.02 1.05 1.42E-08 0.95 0 
0.3541/0.347           
0.3552/0.348 
0.36                                              
(0.29, 0.44)      
11:65323725 rs10896015 
upstrea
m_gene 
OA_hip  G A 1.08 2.30E-07 1.11 2.13E-03 0.73 1.08 1.05 1.11 2.74E-09 0.36 0 
0.7446/0.7299           
0.7491/0.7283 
0.69                                              
(0.62, 0.76)      
11:66501624 rs34419890 
upstrea
m_gene 
OA_hip  T C 1.13 2.70E-07 1.16 8.15E-03 0.93 1.13 1.09 1.18 1.99E-08 0.75 0 
0.9334/0.9249           
0.9401/0.9314 
0.93                                              
(0.88, 0.96)      
11:76506572 rs1149620 
upstrea
m_gene 
OA  T A 1.04 2.50E-09 1.04 8.13E-02 0.57 1.04 1.02 1.05 6.93E-10 0.9 0 
0.58/0.5712           
0.576/0.5668 
0.58                                              
(0.51, 0.65)      
12:59289598 rs79056043 intron OA_hip  G A 1.16 9.50E-07 1.28 6.44E-05 0.05 1.18 1.12 1.24 1.33E-09 0.14 53 
0.0509/0.0444           
0.0651/0.0516 
0.06                                              
(0.03, 0.11)      
12:69637847 rs317630 intron OA  T C 1.03 7.50E-08 1.04 1.79E-01 0.27 1.04 1.02 1.05 1.97E-08 0.75 0 
0.2786/0.2728           
0.2841/0.2755 
0.27                                              
(0.21, 0.34)      
12:90326919 rs11105466 intron 
OA_kne
ehip 
 A G 1.04 8.30E-07 1.07 2.37E-03 0.42 1.04 1.03 1.06 2.15E-08 0.26 
22.
6 
0.4153/0.4152           
0.4285/0.4118 
0.41                                              
(0.34, 0.48)      
12:94167220 rs2171126 intron OA 
OA_kneeh
ip 
T C 1.03 1.30E-08 1.06 6.78E-03 0.51 1.03 1.02 1.05 9.07E-10 0.26 
21.
5 
0.5137/0.5059           
0.5193/0.5044 
0.51                                              
(0.44, 0.59)      
12:122606837 rs11059094 intron OA_hip  T C 1.07 9.80E-09 1.1 9.54E-04 0.48 1.08 1.05 1.1 7.38E-11 0.44 0 
0.4943/0.4769           
0.4967/0.4723 
0.45                                              
(0.37, 0.52)      
12:123835233 rs56116847 
upstrea
m_gene 
OA_kne
e 
OA;OA_kn
eehip 
A G 1.07 4.40E-11 1 9.37E-01 0.36 1.06 1.04 1.08 3.19E-10 0.05 
74.
2 
0.3685/0.3537           
0.3635/0.3628 
0.35                                              
(0.28, 0.43)      
15:50731131 rs35912128 
upstrea
m_gene 
OA_kne
e 
 AT A 1.08 2.20E-08     0.17 1.08 1.05 1.11 2.18E-08 1 0 
0.1717/0.1613           
- 
0.25                                              
(0.19, 0.32)      
15:75097780 rs35206230 
downstr
eam_ge
ne 
OA 
OA_kneeh
ip 
T C 1.04 8.10E-12 1.05 6.44E-02 0.67 1.04 1.03 1.05 1.48E-12 0.86 0 
0.6795/0.67           
0.6725/0.6624 
0.68                                              
(0.61, 0.74)      
16:69735271 rs6499244 
3_prime
_UTR 
OA_kne
e 
OA_kneeh
ip 
A T 1.06 6.40E-10 1.07 5.55E-03 0.56 1.06 1.04 1.08 3.88E-11 0.74 0 
0.4266/0.4414           
0.5768/0.5591 
0.52                                              
(0.45, 0.6)      
16:89704365 rs1126464 
missens
e 
OA  G C 1.04 3.00E-11 0.99 8.88E-01 0.76 1.04 1.03 1.06 1.56E-10 0.07 
69.
3 
0.7638/0.7566           
0.763/0.7644 
0.73                                              
(0.66, 0.8)      
17:2058349 rs35087650 intron 
OA_kne
e 
 ATT A 1.07 1.20E-09     0.26 1.07 1.05 1.1 1.18E-09 1 0 
0.2548/0.241               
- 
0.27                                              
(0.21, 0.35)      
17:29496343 rs2953013 intron 
OA_kne
ehip 
 C A 1.05 1.90E-09 1.05 4.36E-02 0.3 1.05 1.04 1.07 3.07E-10 0.87 0 
0.3047/0.2138           
0.3065/0.2964 
0.27                                              
(0.21, 0.34)      
17:44038785 rs62063281 intron OA_hip  G A 1.1 1.60E-10 1.1 9.13E-03 0.22 1.1 1.07 1.13 5.30E-12 0.91 0 
0.2361/0.2198           
0.2491/0.2321 
0.25                                              
(0.19, 0.32)      
17:44057886 rs547116051 
upstrea
m_gene 
OA  AC A 1.83 1.50E-08     0.0013 1.83 1.49 2.26 1.50E-08 1 0 
0.0006/0.0004           
- 
0 
17:59652282 rs7222178 
interge
nic_regi
on 
OA_hip  A T 1.1 2.60E-10 1.08 1.23E-02 0.2 1.1 1.07 1.13 3.78E-11 0.59 0 
0.2129/0.197           
0.2049/0.1926 
0.18                                              
(0.13, 0.25)      
17:70012939 rs8067763 
interge
nic_regi
on 
OA_kne
e 
 G A 1.06 2.50E-09 1.03 3.83E-01 0.41 1.06 1.04 1.08 2.39E-09 0.35 0 
0.4179/0.4041           
0.4126/0.4055 
0.44                                              
(0.37, 0.51)      
18:20970706 rs10502437 intron OA  G A 1.03 3.60E-08 1.02 3.39E-01 0.6 1.03 1.02 1.04 2.50E-08 0.69 0 
0.6104/0.6042           
0.6096/0.6042 
0.58                                              
(0.51, 0.65)      
19:10750738 rs1560707 
upstrea
m_gene 
OA  T G 1.04 1.70E-13 1.02 1.91E-01 0.37 1.04 1.03 1.05 1.35E-13 0.45 0 
0.3781/0.3683           
0.382/0.3762 
0.4                                              
(0.33, 0.47)      
19:41833784 rs75621460 
downstr
eam_ge
ne 
OA 
OA_kneeh
ip 
A G 1.16 4.40E-15 1.12 1.24E-02 0.03 1.16 1.12 1.2 1.62E-15 0.58 0 
0.0205/0.0178           
0.028/0.0252 
0.03                                              
(0.01, 0.07)      
19:55879672 rs4252548 
missens
e 
OA_hip  T C 1.37 5.30E-13 1.11 1.63E-01 0.02 1.32 1.22 1.43 1.96E-12 0.05 73 
0.0276/0.0214           
0.0258/0.0233 
0.01                                              
(0.002, 
0.04)      
21:40048295 rs2836618 
interge
nic_regi
on 
OA_hip 
OA_kneeh
ip 
A G 1.08 1.90E-07 1.18 2.17E-06 0.26 1.09 1.06 1.12 3.20E-11 0.02 
82.
6 
0.2753/0.2609           
0.2846/0.2524 
0.19                                              
(0.14, 0.26)      
22:43662241 rs528981060 
upstrea
m_gene 
OA  A G 1.68 2.40E-08     0.001 1.68 1.4 2.02 2.37E-08 1 0 
0.0012/0.0008           
- 
- 
Previously reported loci                                     
1:219753509 rs2820443 
interge
nic_regi
on 
OA_kne
ehip 
OA_hip;O
A 
C T 1.06 9.90E-10 1.06 1.20E-02 0.3 1.06 1.04 1.07 6.01E-11 0.82 0 
0.3079/0.2968           
0.312/0.2993 
0.26                                              
(0.2, 0.34)      
2:70717653 rs3771501 intron OA 
OA_hip;O
A_kneehip 
A G 1.05 6.00E-15 1.06 1.31E-02 0.47 1.05 1.03 1.06 4.24E-16 0.67 0 
0.4838/0.4727           
0.489/0.4753 
0.48                                              
(0.4, 0.55)      
3:52817778 rs3774355 
upstrea
m_gene 
OA_hip 
OA_kneeh
ip 
A G 1.09 3.00E-10 1.15 2.07E-05 0.36 1.09 1.07 1.12 8.20E-14 0.12 59 
0.3776/0.358           
0.3893/0.3574 
0.39                                              
(0.32, 0.47)      
6:45357699 rs2396502 intron OA_hip 
OA_kneeh
ip 
C A 1.09 1.80E-10 1.1 2.23E-03 0.6 1.09 1.06 1.11 2.12E-12 0.74 0 
0.6218/0.6019           
0.622/0.5997 
0.64                                              
(0.57, 0.71)      
6:76164589 rs12209223 
upstrea
m_gene 
OA_hip  A C 1.16 2.50E-12 1.23 7.79E-06 0.1 1.17 1.13 1.21 3.88E-16 0.26 22 
0.113/0.0998           
0.1242/0.1036 
0.09                                              
(0.06, 0.15)      
9:4291928 rs10974438 intron OA 
OA_kneeh
ip 
A C 1.03 1.10E-07 1.06 6.39E-03 0.65 1.03 1.02 1.05 1.34E-08 0.36 0 
0.6567/0.6494           
0.658/0.6456 
0.63                                              
(0.55, 0.7)      
9:119484132 rs34687269 intron OA_hip  A T 1.08 1.70E-10 1.1 1.67E-03 0.53 1.09 1.06 1.11 1.67E-12 0.7 0 
0.5499/0.5299           
0.5555/0.5323 
0.52                                              
(0.45, 0.6)      
12:28014970 rs10492367 
interge
nic_regi
on 
OA_hip 
OA_kneeh
ip 
T G 1.16 2.90E-19 1.21 4.38E-07 0.19 1.16 1.13 1.2 1.25E-24 0.25 
24.
5 
0.2093/0.187           
0.2187/0.1877 
0.18                                              
(0.13, 0.25)      
15:58215727 rs4775006 
interge
nic_regi
on 
OA_kne
e 
 A C 1.05 1.30E-07 1.12 2.58E-04 0.41 1.06 1.04 1.08 8.40E-10 0.08 
68.
3 
0.4227/0.41           
0.437/0.4104 
0.36                                              
(0.29, 0.44)      
15:67370506 rs12901372 intron OA_hip  C G 1.07 2.90E-08 1.13 5.22E-05 0.53 1.08 1.06 1.11 3.46E-11 0.13 
56.
2 
0.5486/0.5319           
0.5648/0.5347 
0.47                                             
(0.4, 0.55)      
16:53799977 rs9930333 intron 
OA_kne
ehip 
 G T 1.04 4.30E-07 1.1 2.57E-04 0.42 1.05 1.03 1.06 1.52E-09 0.04 
75.
8 
0.4316/0.4212           
0.4471/0.4245 
0.42                                              
(0.35, 0.49)      
20:34025756 rs143384 
5_prime
_UTR 
OA_kne
e 
OA_kneeh
ip;OA 
A G 1.1 3.60E-22 1.07 9.24E-03 0.6 1.1 1.08 1.12 4.77E-23 0.37 0 
0.619/0.5959           
0.6026/0.5865 
0.64                                              
(0.57, 0.71)      
 
 
 
Most Severe Consequence: Most severe consequence of index variant as predicted by SNPEff; Trait UKBiobank: Osteoarthritis trait most significantly 
associated with variant in the meta-analysis stage; Other Traits gwas sign metaanalysis: Other osteoarthritis traits with genome-wide significant association 
following meta-analysis; EA: Effect allele; NEA: Non-effect allele; OR: Odds ratio; PV: P value; WEAF: Weighted effect allele frequency between UK Biobank 
and arcOGEN; OR_95L: Lower bound of the 95% credible interval of the odds ratio; OR_95U: Upper bound of the 95% credible interval of the odds ratio; 
q_pv: P value of Cochran’s Q measure of heterogeneity; i2: I² statistic describing the percentage of variation across studies that is due to heterogeneity 
rather than chance; OA: osteoarthritis; OA_hip: Hip osteoarthritis; OA_knee: Knee osteoarthritis; OA_kneehip: Knee and/or hip osteoarthritis; * UK Biobank 
allele frequencies are displayed at the top with arcOGEN below. **1000 Genomes Project GBR lower and upper 95% confidence intervals for the EAF are 
displayed in brackets.
Table 2: Translational context for selected osteoarthritis-associated genes. 
 
Gene OA 
phenotype 
OA locus Chr: 
index variant 
MOA 
needed for 
OA, if 
known† 
Drug 
targeting OA 
gene 
Dev. Phase Molecul
e type 
Drug 
MOA 
Current 
Indication(s) 
TGFB1 OA; 
OA_kneehip 
Chr19: 
rs75621460 
Agonist / 
upregulator 
INVOSSA Registered Cell 
therapy 
↑expressi
on 
Knee osteoarthritis 
GDF5 OA_knee; 
OA_kneehip
; OA 
Chr20: rs143384 Agonist / 
upregulator 
HMR-4052 Clinical 
development 
Protein ↑signallin
g 
Regeneration, 
cartilage, 
intervertebral disc 
FGF18 OA_kneehip Chr5: rs3884606 
 
Agonist / 
upregulator 
AS-902330 Clinical 
development 
Protein ↑signallin
g 
Osteoarthritis, 
cartilage 
regeneration 
CTSK OA; OA_hip 1:150214028 
_CT_C 
Unknown CTSK inhibitor Clinical 
development 
SM Inhibitor Osteoarthritis 
IL11 OA_hip chr19: rs4252548 ↑ IL11 
signalling? 
Oprelvekin Approved Protein ↑ IL11 
signalling 
Thrombocytopenia 
DPEP1 OA Chr16: 
rs1126464 
Unknown CILASTATIN Approved SM Inhibitor Co-administered 
with imipenem 
(antibiotic) to 
prolong effective 
dose 
DIABLO OA_hip Chr12:  
rs11059094 
 
Unknown LCL-161  Clinical 
development 
SM SMAC 
mimetic 
and IAP 
inhibitor 
Breast cancer, 
leukemia, 
myeloma 
CRHR1 OA_hip Chr17:  
rs62063281 
Inhibitor NBI-74788 Clinical 
development 
SM Antagonis
t 
Adrenal 
insufficiency, 
primary, 
congenital 
MAPT OA_hip Chr17:  
rs62063281 
Inhibitor flortaucipir F 
18, Leuco-
methylthionin
ium 
Clinical 
development 
SM Tau 
aggregati
on 
inhibitor 
Alzheimer's 
disease 
TNFSF15 OA; OA_hip; 
OA_kneehip
; OA_knee 
Chr9: rs919642, 
rs1330349 
Unknown PF-06480605 
 
Clinical 
development 
Ab Inhibitor Ulcerative colitis, 
Wet AMD  
OA: osteoarthritis; OA_hip: Hip osteoarthritis; OA_knee: Knee osteoarthritis; OA_kneehip: Knee 
and/or hip osteoarthritis; SM: small molecule; Ab: Antibody; MOA: mechanism of action of a 
therapeutic; †Based on functional evidence supporting the gene as an osteoarthritis risk factor. 
Criteria for inclusion of “OA locus” gene: target has a therapeutic approved or in clinical 
development; therapeutic with OA indication and/or target eQTL colocalization with index variant 
and/or target missense variant with posterior probability of colocalization >0.5. Drug data compiled 
from Chembl ( https://www.ebi.ac.uk/chembl/ ) and Clinical trials.gov 
(https://www.clinicaltrials.gov/ ). 
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